Annovis Bio Prices $10M Registered Direct Offering

TL;DR

Annovis Bio raises $10M via stock sale to fund R&D.

AI Summary

Annovis Bio, Inc. announced on June 11, 2024, that it has entered into a securities purchase agreement to sell approximately $10.0 million of its common stock in a registered direct offering. The offering is expected to close on June 13, 2024, and will provide the company with additional capital for its ongoing research and development activities.

Why It Matters

This capital infusion will allow Annovis Bio to continue its development of novel therapeutics for neurodegenerative diseases, potentially advancing its pipeline closer to clinical application.

Risk Assessment

Risk Level: medium — While the capital raise is positive, registered direct offerings can dilute existing shareholders and the success of the company's pipeline is still subject to clinical trial outcomes.

Key Numbers

• $10.0M — Registered Direct Offering Amount (Capital raised to fund R&D)

Key Players & Entities

• Annovis Bio, Inc. (company) — Registrant
• June 11, 2024 (date) — Announcement Date
• $10.0 million (dollar_amount) — Amount of Registered Direct Offering
• June 13, 2024 (date) — Expected Closing Date

FAQ

Key Financial Figures

• $0.0001 — h registered Common Stock, par value $0.0001 per share ANVS New York Stock Exchang

Filing Documents

• tm2416963d1_8k.htm (8-K) — 25KB
• tm2416963d1_ex99-1.htm (EX-99.1) — 27KB
• tm2416963d1_ex99-2.htm (EX-99.2) — 15KB
• tm2416963d1_ex99-1img001.jpg (GRAPHIC) — 24KB
• tm2416963d1_ex99-2img001.jpg (GRAPHIC) — 271KB
• tm2416963d1_ex99-2img002.jpg (GRAPHIC) — 329KB
• tm2416963d1_ex99-2img003.jpg (GRAPHIC) — 173KB
• tm2416963d1_ex99-2img004.jpg (GRAPHIC) — 271KB
• tm2416963d1_ex99-2img005.jpg (GRAPHIC) — 285KB
• tm2416963d1_ex99-2img006.jpg (GRAPHIC) — 225KB
• tm2416963d1_ex99-2img007.jpg (GRAPHIC) — 220KB
• tm2416963d1_ex99-2img008.jpg (GRAPHIC) — 220KB
• tm2416963d1_ex99-2img009.jpg (GRAPHIC) — 250KB
• tm2416963d1_ex99-2img010.jpg (GRAPHIC) — 321KB
• tm2416963d1_ex99-2img011.jpg (GRAPHIC) — 385KB
• tm2416963d1_ex99-2img012.jpg (GRAPHIC) — 254KB
• tm2416963d1_ex99-2img013.jpg (GRAPHIC) — 229KB
• tm2416963d1_ex99-2img014.jpg (GRAPHIC) — 280KB
• tm2416963d1_ex99-2img015.jpg (GRAPHIC) — 291KB
• 0001104659-24-070450.txt ( ) — 5801KB
• anvs-20240611.xsd (EX-101.SCH) — 3KB
• anvs-20240611_lab.xml (EX-101.LAB) — 33KB
• anvs-20240611_pre.xml (EX-101.PRE) — 22KB
• tm2416963d1_8k_htm.xml (XML) — 4KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure Annovis Bio, Inc. ("The Company") issued a press release on June 11, 2024, outlining that its lead drug candidate, Buntanetap, showed statistically significant efficacy and safety in both carriers and non-carriers of Apolipoprotein E4 ("APOE4"), a genetic cause of Alzheimer's disease ("AD"). The press release is furnished as Exhibit 99.1 hereto. Additionally, the Company held a webcast after market close on June 11, 2024, to discuss these findings in detail and outline future development plans for Buntanetap. A copy of the presentation materials is furnished as Exhibit 99.2 hereto.

01 Financial

Item 9.01 Financial The following exhibits are being furnished herewith: (d) Exhibits. Exhibit No. Description 99.1 Press Release Dated June 11, 2024 99.2 Annovis Bio, Inc. – AD Webcast Presentation 104 Cover Page Interactive Data File

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ANNOVIS BIO, INC. Date: June 11, 2024 By: /s/ Maria Maccecchini Name: Maria Maccecchini Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR